HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Ready To Change Bioequivalence Standards, Pending Advisory Committee Input

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency appears ready to narrow bioequivalence standards across the board for generic drug approvals and set up specific requirements for certain drugs with complicated dosing, but is looking to the Pharmaceutical Science advisory panel for final advice on whether the moves are necessary.
Advertisement

Related Content

ANDAs For Narrow Therapeutic Index Drugs May Need Crossover Studies
ANDAs For Narrow Therapeutic Index Drugs May Need Crossover Studies
Generics For Risperdal Consta Need Multi-Dose Testing, J&J Argues
Generics For Risperdal Consta Need Multi-Dose Testing, J&J Argues
FDA Reverses Stance On Bioequivalence Standards For Mesalamine
FDA Reverses Stance On Bioequivalence Standards For Mesalamine
Changes To Generic Drug Bioequivalence Requirements Could Mean Higher Study Costs
Changes To Generic Drug Bioequivalence Requirements Could Mean Higher Study Costs
FDA Aims To Bolster Generics' Image With Research, Regulatory Changes
FDA Aims To Bolster Generics' Image With Research, Regulatory Changes

Topics

Advertisement
UsernamePublicRestriction

Register

PS070473

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel